Attached files
file | filename |
---|---|
EX-32.1 - EX-32.1 - Karyopharm Therapeutics Inc. | d529132dex321.htm |
EX-31.2 - EX-31.2 - Karyopharm Therapeutics Inc. | d529132dex312.htm |
EX-31.1 - EX-31.1 - Karyopharm Therapeutics Inc. | d529132dex311.htm |
EX-23.1 - EX-23.1 - Karyopharm Therapeutics Inc. | d529132dex231.htm |
EX-21.1 - EX-21.1 - Karyopharm Therapeutics Inc. | d529132dex211.htm |
EX-10.30 - EX-10.30 - Karyopharm Therapeutics Inc. | d529132dex1030.htm |
10-K - 10-K - Karyopharm Therapeutics Inc. | d529132d10k.htm |
Exhibit 12.1
STATEMENT REGARDING COMPUTATION OF CONSOLIDATED RATIOS OF EARNINGS TO FIXED CHARGES AND RATIOS OF EARNINGS TO COMBINED FIXED CHARGES AND PREFERRED STOCK DIVIDENDS
Fiscal Year Ended December 31, | ||||||||||||||||||||
2017 | 2016 | 2015 | 2014 | 2013 | ||||||||||||||||
Loss from operations |
(128,984 | ) | (110,732 | ) | (119,076 | ) | (75,846 | ) | (33,950 | ) | ||||||||||
add: Fixed charges (see below) |
399 | 383 | 344 | 173 | 58 | |||||||||||||||
|
|
|
|
|
|
|
|
|
|
|||||||||||
Pre-tax loss from continuing operations plus fixed charges |
(128,585 | ) | (110,349 | ) | (118,732 | ) | (75,673 | ) | (33,892 | ) | ||||||||||
Fixed charges: |
||||||||||||||||||||
Interest expense on indebtedness |
| | | | | |||||||||||||||
Interest expense on portion of rent expense representative of interest |
399 | 383 | 344 | 173 | 58 | |||||||||||||||
|
|
|
|
|
|
|
|
|
|
|||||||||||
Total fixed charges |
399 | 383 | 344 | 173 | 58 | |||||||||||||||
|
|
|
|
|
|
|
|
|
|
|||||||||||
Ratio of earnings to fixed charges |
| | | | | |||||||||||||||
|
|
|
|
|
|
|
|
|
|
|||||||||||
Deficiency of earnings available to cover fixed charges |
(128,984 | ) | (110,732 | ) | (119,076 | ) | (75,846 | ) | (33,950 | ) | ||||||||||
|
|
|
|
|
|
|
|
|
|
$ in thousands